BIOTECH SECURITY TOKEN INITIAL EXCHANGE OFFER (IEO)
ADVISED BY DR GORAN ANDO
PROOF OF CONCEPT Proof of Concept has already been achieved in the native therapeutic protein of interest. This is rarely the case in Biotech Discovery Projects. Through this, Banksia has an almost ‘unfair advantage’ in its pathway into the clinic and Human Clinical Trials .
A Tokenised Royalty Stream Offer like this is truely innovative, and stands to totally transform the global Biotech funding paradigm. Blockchain for the ﬁrst time has made this kind of offer logistically possible, bringing Biotech investment to the people!
Banksia’s BaRA technology has been secured under a Provisional Patent. Freedom to Operate and Patentability studies were undertaken by a ‘top tier’ Patent Law Firm. Our IP Management Strategy will be a driving force in Product Development
BANKSIA SECURES THE RIGHTS TO COMMERCIALIZE A BIOLOGICAL GOLD MINE
FULLY OPERATIONAL BaRA Token sales steadily fund the development of the BaRA Rheumatoid Arthritis therapeutic. Development and Clinical Milestones drive the token value.
HARNESSING THE POWER OF NATURE
ROYALTIES 50% SALE
ROYALTY DEAL STATS 25%
BaRA Tokens are listed on further exchanges with larger volumes. Marketing is ramped-up in parallell
6 STEP PLAN
30 Million BaRA Tokens are allocated to ‘incentives’. Investment pre-listing to enable the ‘listing event’ is eligible to a substantial portion of this pool
WE ARE HERE
Banksia will initially list each BaRA Token at:
Banksia lists (IEO) its BaRA Security tokens on a mid-tier exchange and undertakes marketing activities
The native form of Banksia’s therapeutic protein was found to be 10 to 100 times more effective at suppressing TNF in whole human blood than the ‘Big Three’ leading drugs currently on the market
In a scenario where Banksia took 10% of this market on only a 10% royalty rate, each BARA Token would have yielded approximately US$4.00 per Token in that year alone...
RAMP-UP Banksia has tokenized 50% of its future royalty stream of it’s BaRA Product. The proceeds of the ‘on exchange sale’ of these tokens will be used to fund the development and clinical trials of BaRA, and company activities
The top earning Anti-TNFs Hunira, Remicade & Enbrel earned US$31.87 Billion in 2015
The Inﬂammation Market is expected to reach 8.5 Million people by 2023 (~2% of the world’s population).
INTELLECTUAL PROPERTY 3
US$31.9 BILLION 8.5 MILLION
The Rheumatoid Arthritis market is projected to be US$80.7 Billion by 2020
The Large Pharmaceutical companies are stereotypically relationship focused when it comes to ‘deal doing’. Having efﬁcient and direct access to the decision makers will be vital for Banksia to achieve its Royalty Deal objectives
Key and foundational patents for all the ‘Big Three’ Anti-TNF Drugs have or will expire in the near future, creating an opening for generics and new therapies such as Banksia’s Anti-TNF
In February 2018, the Biotech Nektar achieved a staggering 65% Royalty Deal with Bristol Meyers Squibb (BMS). A comparable deal for Banksia would be game changing
Former Chairman of Novo Nordisk A/S and Founding Fellow of the American College of Rheumatology. A highly respected and networked individual in the Pharmaceutical industry. A critical factor in deal doing.
Over 50 years combined Biotech, Board and C-Suite experience. Proven fund raisers in both Listed and Start-up Biotech companies. A potent blend of business, scientiﬁc and creative minds.
PRELISTING Establish web presence social media and BaRA Token minting & Storage
STRETCH NEKTAR GOAL DEAL
DISCOVERY BaRA Discovery Studies and planning phase. Key Personnel, Advisors and Service Providers engaged and secured
IP SECURED Provisional Patent, Patentability Study & Freedom to Operate
Note that this Infographic does not constitute an ‘Offer’ any investment will require formal and complete Offer Documentation to be acknowledged